Click on headlines below to download research

Scaling up for commercialisation
Amoeba | 22/05/2023

Following on from the press release in March that provided preliminary data on the FY22 results, Amoéba has published its FY22 universal registration…

Building on an exceptional year
Amoeba | 03/04/2023

FY22 was an exceptional year for Amoéba in which it secured regulatory approval in the United States and a recommendation for approval in the European…

Fighting pathogens, respecting nature
Amoeba | 13/03/2023

During 2022 Amoéba secured regulatory approval in the United States and a recommendation for approval in the European Union for the active substance…